CRANBURY, N.J. — Cornerstone Pharmaceuticals, Inc., (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase …
- Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 for the Treatment of Small Cell …
- Cornerstone Pharmaceuticals to Present CPI-613 Phase I Results at 2013 American Society of Hematology Annual Meeting